



For Immediate Release

NOTED OREGON CARDIOLOGISTS CONDUCT FIRST STUDY ON ADULTS USING VENTRIPOINT 3D HEART ANALYSIS TECHNOLOGY

SEATTLE, WASHINGTON, April 4, 2011 – VentriPoint Diagnostics Ltd. (together with its wholly owned subsidiary, VentriPoint, Inc., “VentriPoint”) (TSXV: VPT; OTC: VPTDF.PK) announces that the Adult Congenital Heart Disease team at Oregon Health & Science University (OHSU) in Portland, Oregon, will be using the VentriPoint Medical System (VMS) with its breakthrough and patented technology to study adults with congenital heart disease. OHSU is the second U.S. hospital to install a VMS and their study will be conducted by Dr. David Sahn, and Dr. Craig Broberg, from its Adult Congenital Heart Program.

“As an early collaborator of VentriPoint, we are excited to participate. The VMS can give us a new, clear and highly accurate picture of the right heart in 3D – the hidden part of the heart - using a relatively cheap and readily-available technology that has been around for decades, 2D ultrasound,” Dr. Sahn stated.

Those suffering from congenital heart disease require life-long monitoring. Prior to the VMS, the only other methods to get a readable and accurate picture of the right ventricle were to use an expensive and hard-to-access MRI or a CT that uses relatively high dosages of radiation.

The incidence rate of congenital heart disease in the United States is about 8 per 1,000 live births with approximately 1 million adults and 800,000 children currently living with congenital heart disease in the U.S.

As part of a controlled deployment plan, VentriPoint has successfully installed its medical systems in Toronto, Canada; in Europe at the Rikshospitalet University Hospital in Oslo, Norway; and in the U.S. at the University of Nebraska Medical Center/Creighton University Joint Division of Pediatric Cardiology at Children’s Hospital & Medical Center in Omaha, Nebraska, and now at the Oregon Health & Science University in Portland, Oregon. Additional VMS installations are in process and will be announced as each system becomes operational. VentriPoint expects to have at least ten of its systems installed and operational in the US, Europe and Canada by the end of the second calendar quarter.

“It is rewarding to work with the leading Oregon cardiologists who see the immediate need for our technology to replace and augment expensive MRI procedures”, said Dr. Adams, CEO of VentriPoint, “VentriPoint is focused on cardiovascular disease and strives to deliver products that solve real world problems as identified by the Oregon Health & Science University and other centers in the U.S., Europe and Canada.”

About Dr. Sahn and Dr. Broberg

Dr. Sahn is an expert in cardiac imaging in the field of pediatric and adult congenital heart disease and his dedication in NIH peer review earned him recognition as the first Marcy Speer Outstanding Reviewer Award honoree. Dr. Sahn is a Professor of Pediatrics, Diagnostic Radiology and Biomedical Engineering and Director of the Interdisciplinary Program for Cardiac Imaging at Oregon Health & Science University.

Dr. Broberg is the Director of the Adult Congenital Heart Program at OHSU, and is a funded investigator studying congenital heart disease. He completed his cardiology fellowship training at OHSU in 2003 and joined the Division of Cardiology in 2005 after an additional two-year fellowship in congenital heart disease and imaging at the Royal Brompton Hospital in London.

About VentriPoint Diagnostics Ltd.

VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a multibillion dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of VentriPoint's VMS™ diagnostic tool and VentriPoint is pursuing the US-FDA approval through the 510(k) process.

For further information, please contact:

VentriPoint Diagnostics Ltd.

Dr. George Adams, CEO
Telephone: (206) 283-0221, ext. 401
email: gadams@ventripoint.com

Investor and Media Contacts:

Howard Group Inc.

Peter Weichler/David Burwell
Telephone: 1.888-221-0915 or 403-221-0915
email: Peter@howardgroupinc.com or
Dave@howardgroupinc.com

Cautionary Note Regarding Forward-Looking Statements - Certain statements contained herein constitute forward-looking statements, including statements concerning the anticipated closing date of the Offering and the anticipated use of proceeds. We believe the expectations reflected in those forward-looking statements are reasonable but no assurance can be given that these expectations will prove to be correct and such forward-looking statements included herein should not be unduly relied upon. Closing could be delayed if VentriPoint cannot obtain necessary regulatory approvals within anticipated timelines and will not be completed unless certain conditions customary for transactions of this kind are satisfied. The forward-looking statements included in this press release are made as of the date of this press release and VentriPoint disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release